LBA-3, a selective and orally active inhibitor of the sodium-coupled citrate transporter SLC13A5, exhibits an IC50 of 67 nM. This compound effectively reduces triglyceride and total cholesterol levels in both oleic and palmitic acid (OPA)-stimulated AML12 cells and PCN-stimulated primary mouse hepatocytes, as well as in mouse models, without showing detectable toxicity. Additionally, LBA-3 is permeable to the blood-brain barrier [1].

在Sprague Dawley大鼠中，LBA-3 (50 mg/kg，口服，单剂量) 的药代动力学性质显示，其血浆最高浓度C max 达到288262.00 μg/L，总体曝光量AUC为704570.43 h/μg –1·L，口服生物利用度则为48.67% [1]。